Lexicon Pharmaceuticals(LXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LXRX Lexicon Pharmaceuticals

Closed 05-26 16:00:00 EDT

2.06

-0.10

-4.63%

盘后2.07

+0.01+0.54%

19:14 EDT

High2.22	Low2.04	Vol3.07M
Open2.21	D1 Closing2.16	Amplitude8.31%
Mkt Cap914.64M	Tradable Cap861.08M	Total Shares444.00M
T/O6.40M	T/O Rate0.74%	Tradable Shares418.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LXRX","market":"US","secType":"STK","nameCN":"Lexicon Pharmaceuticals","latestPrice":2.06,"timestamp":1779825600000,"preClose":2.16,"halted":0,"volume":3074553,"hourTrading":{"tag":"盘后","latestPrice":2.0712,"preClose":2.06,"latestTime":"19:14 EDT","volume":7995,"amount":16541.3397,"timestamp":1779837291169,"change":0.0112,"changeRate":0.005437,"amplitude":0.005437},"delay":0,"changeRate":-0.046296296296296335,"floatShares":418000000,"shares":444000000,"eps":-0.070019,"marketStatus":"Closed","change":-0.1,"latestTime":"05-26 16:00:00 EDT","open":2.21,"high":2.2195,"low":2.04,"amount":6400641.330036,"amplitude":0.083102,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.070019,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1779868800000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":955080000000,"exchange":"NASDAQ","adjPreClose":2.16,"preHourTrading":{"tag":"盘前","latestPrice":2.2,"preClose":2.16,"latestTime":"09:28 EDT","volume":4239,"amount":9238.756374,"timestamp":1779802136067,"change":0.04,"changeRate":0.018519,"amplitude":0.023148},"postHourTrading":{"tag":"盘后","latestPrice":2.0712,"preClose":2.06,"latestTime":"19:14 EDT","volume":7995,"amount":16541.3397,"timestamp":1779837291169,"change":0.0112,"changeRate":0.005437,"amplitude":0.005437},"volumeRatio":1.729801,"impliedVol":0.5811,"impliedVolPercentile":0.0598},"requestUrl":"/m/hq/s/LXRX","defaultTab":"news","newsList":[{"id":"1145709187","title":"Stock Track | Lexicon Pharmaceuticals Soars 5.63% Intraday on Investor Conference Participation Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=1145709187","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145709187?lang=en_us&edition=fundamental","pubTime":"2026-05-12 21:59","pubTimestamp":1778594388,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals (LXRX) saw its stock price soar 5.63% during Tuesday's intraday trading session following a company announcement regarding upcoming investor engagement.The biopharmaceutical...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["LXRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634823211","title":"Lexicon Pharmaceuticals to present at H.C. Wainwright BioConnect Investor Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2634823211","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634823211?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:31","pubTimestamp":1778589089,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals management to join fireside chat at 4th Annual H.C. Wainwright BioConnect Investor Conference on May 19, 2026, at Nasdaq World Headquarters in New York City","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL17vWLC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","SG9999014039.USD","BK4588","LU2095319765.USD","LU2210149790.SGD","IE00BKPKM429.USD","IE00BN0W2T93.GBP","SG9999014013.SGD","BK4139","LU0314104364.USD","IE00B64PRP62.GBP","LXRX","IE00BGHQF748.EUR","NDAQ","IE00BN0W2W23.USD","BK4585","IE00B3QW5Z07.USD","SG9999014005.SGD","IE00BN0W2V16.EUR","BK4007","SG9999014021.USD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634223876","title":"Lexicon Pharma Is Maintained at Buy by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2634223876","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634223876?lang=en_us&edition=fundamental","pubTime":"2026-05-11 23:19","pubTimestamp":1778512740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LXRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 11, 2026 11:19 ET (15:19 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXRX","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633430140","title":"Lexicon Pharmaceuticals: Buy Rating Reiterated as Value Catalysts Build; $6 Price Target Maintained","url":"https://stock-news.laohu8.com/highlight/detail?id=2633430140","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633430140?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:55","pubTimestamp":1778237724,"startTime":"0","endTime":"0","summary":"Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on Lexicon Pharmaceuticals, retaining the price target of $6.00. Joseph Pantgin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/lexicon-pharmaceuticals-buy-rating-reiterated-as-value-catalysts-build-6-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/lexicon-pharmaceuticals-buy-rating-reiterated-as-value-catalysts-build-6-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LXRX","BGSX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633102923","title":"Lexicon Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2633102923","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633102923?lang=en_us&edition=fundamental","pubTime":"2026-05-08 09:47","pubTimestamp":1778204838,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings SummaryLexicon Pharmaceuticals Inc LXRX.OQ reported quarterly breakeven results per share for the quarter ended Ma","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L03H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LXRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633149187","title":"Lexicon Q1 FY26 net loss narrows to $1 million; revenue rises to $21.1 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633149187","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633149187?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:36","pubTimestamp":1778153781,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals posted revenue of $21.1 million for first-quarter 2026, swinging from $1.3 million a year earlier as $20 million of Novo Nordisk development milestones supplemented $1.1 million of INPEFA net sales.Net loss narrowed to $1 million, or less than $0.01 per share, from a loss of $25.3 million, or $0.07 per share, a year earlier.R&D expense fell to $12.8 million from $15.3 million, due to completion of PROGRESS Phase 2b and licensing of LX9851; SG&A dropped to $9.2 million from $11.6 million on reduced INPEFA marketing and lower personnel costs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexicon Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL8y0G5K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXRX","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633149381","title":"Lexicon Pharmaceuticals Q1 Sales $1.090M Miss $9.380M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2633149381","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633149381?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:31","pubTimestamp":1778153472,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals (NASDAQ:LXRX) reported quarterly sales of $1.090 million which missed the analyst consensus estimate of $9.380 million by 88.38 percent.  This is a 13.63 percent decrease over sales of $1.262","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52361466/lexicon-pharmaceuticals-q1-sales-1-090m-miss-9-380m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633114984","title":"BRIEF-Lexicon Pharmaceuticals Q1 EPS USD -0.01","url":"https://stock-news.laohu8.com/highlight/detail?id=2633114984","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633114984?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:30","pubTimestamp":1778153448,"startTime":"0","endTime":"0","summary":"BRIEF-Lexicon Pharmaceuticals Q1 EPS USD -0.01\n\n\nMay 07 (Reuters) - Lexicon Pharmaceuticals Q1 operating expenses USD 22.098 million.\n\nQ1 operating income USD -996 thousand\nQ1 product revenue USD 1.09 million\nQ1 net income USD -1.043 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nPLX9AB942:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXRX","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633149460","title":"Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2633149460","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633149460?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:30","pubTimestamp":1778153400,"startTime":"0","endTime":"0","summary":"SONATA-HCM anticipated to be fully enrolled mid-2026 Resubmission of NDA for ZYNQUISTA in type 1 diabetes anticipated mid-2026 with potential for approval this year Clinical development of LX9851 init","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3289862/0/en/Lexicon-Pharmaceuticals-Reports-First-Quarter-2026-Financial-Results-and-Provides-Clinical-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0154236417.USD","BK4178","IE00BZ1G4Q59.USD","BK4007","NVOX","BK4588","BK4585","BK4599","HCM","BK4531","NVO","LU1093756325.SGD","NVOH","IE00BKVL7J92.USD","AAN","LU1093756168.USD","BK4532","BK4139","LXRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633168005","title":"Lexicon Pharmaceuticals Secures New Hercules Term Loan Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2633168005","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633168005?lang=en_us&edition=fundamental","pubTime":"2026-05-07 05:38","pubTimestamp":1778103538,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals ( ($LXRX) ) just unveiled an announcement. On May 4, 2026, Lexicon Pharmaceuticals entered a loan and security agreement wi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lexicon-pharmaceuticals-secures-new-hercules-term-loan-facility?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lexicon-pharmaceuticals-secures-new-hercules-term-loan-facility?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LXRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633151522","title":"Lexicon enters USD 100 million loan facility with Hercules Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2633151522","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633151522?lang=en_us&edition=fundamental","pubTime":"2026-05-07 04:07","pubTimestamp":1778098062,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals entered loan facility with Hercules Capital providing up to USD 100 million in borrowing capacity.USD 55 million funded at closing to repay existing Oxford Finance loan facility.Additional USD 20 million tranche available subject to clinical, regulatory, financial milestones; further USD 25 million tranche available after second draw, subject to Hercules consent.Facility carries floating rate at prime plus 3.1% with floor of 9.85%; includes 18-month interest-only period with up to two six-month extensions.Maturity set for May 4, 2030; obligations secured by first-lien interest on all assets with minimum cash covenant starting June 1, 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexicon Pharmaceuticals In","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDL5JGpPg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXRX","BK4139","BK4135","HTGC","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633994844","title":"Lexicon Pharmaceuticals Inc  expected to post a loss of 3 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2633994844","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633994844?lang=en_us&edition=fundamental","pubTime":"2026-05-05 20:32","pubTimestamp":1777984353,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals Inc  expected to post a loss of3cents a share - Earnings Preview Lexicon Pharmaceuticals Inc LXRX.OQ LXRX.O is expected to  show a rise in quarterly revenue when it reports  re","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nL8N41I1I1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LXRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633965879","title":"Lexicon Pharmaceuticals : Loan Facility Provides for an Initial Interest-Only Period of 18 Months, With Potential for Two Six-Month Extensions","url":"https://stock-news.laohu8.com/highlight/detail?id=2633965879","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633965879?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:05","pubTimestamp":1777925100,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nTUA3QP8DM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HTGC","BK4139","LXRX","BK4007","BK4135"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633963787","title":"Lexicon Pharmaceuticals Announces $100 Million Loan Facility With Hercules Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2633963787","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633963787?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:05","pubTimestamp":1777925100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nTUA3QP8DM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LXRX","BK4135","BK4139","HTGC","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633585965","title":"Lexicon Pharmaceuticals: Under Terms, Initial $55 Mln Tranche Will Be Used to Repay Existing Loan Facility With Oxford Finance","url":"https://stock-news.laohu8.com/highlight/detail?id=2633585965","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633585965?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:05","pubTimestamp":1777925100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nTUA3QP8DM:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4007","HTGC","BK4135","LXRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633965507","title":"Press Release: Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2633965507","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633965507?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:05","pubTimestamp":1777925100,"startTime":"0","endTime":"0","summary":"THE WOODLANDS, Texas, May 04, 2026  -- Lexicon Pharmaceuticals, Inc.  announced today that it has entered into a loan facility with Hercules Capital, Inc.  that provides up to $100 million in borrowing capacity. Access to this non-dilutive capital provides Lexicon with greater financial flexibility through both an extended interest-only period and maturity date and the opportunity to further strengthen its balance sheet to support pivotal upcoming regulatory and commercial milestones.\"Hercules Capital is pleased to support Lexicon Pharmaceuticals with a flexible financing solution that will support it through upcoming clinical and regulatory milestones,\" said Adam Soller, Managing Director. \"This partnership underscores our commitment to funding innovative therapies that address significant unmet medical needs.\". Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients' lives. Lexicon has a pipeline of drug candidates in discovery, preclinic","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4531","BK4135","BK4007","LXRX","BK4588","HTGC","BK4585","HCM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632669305","title":"Lexicon Pharmaceuticals shareholders approved increase in authorized common shares to 900 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2632669305","media":"Reuters","labels":["executive","shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632669305?lang=en_us&edition=fundamental","pubTime":"2026-05-01 04:26","pubTimestamp":1777580798,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals held annual shareholder meeting April 30, 2026.Shareholders backed Seventh Amended and Restated Certificate of Incorporation, lifting authorized common stock to 900 million shares from 450 million shares.Stockholders also adopted 2026 Equity Incentive Plan, raising share pool to 90 million shares from 75 million shares.Vote also adopted 2026 Non-Employee Directors' Equity Incentive Plan, increasing share pool to 6 million shares from 4 million shares.Ernst & Young was ratified as independent auditor for fiscal 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexicon Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Ret","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDL3ynd6X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","LXRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631634938","title":"Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2631634938","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631634938?lang=en_us&edition=fundamental","pubTime":"2026-04-30 20:00","pubTimestamp":1777550400,"startTime":"0","endTime":"0","summary":"THE WOODLANDS, Texas, April  30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its first quarter 2026 financial results on Thursday, Ma","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/30/3284770/0/en/Lexicon-Pharmaceuticals-to-Report-First-Quarter-2026-Financial-Results-on-May-7-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXRX","BK4585","BK4139","BK4007","BK4531","HCM","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628020529","title":"Lexicon says Phase 2b data support pilavapadin 10 mg for Phase 3 DPNP trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2628020529","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628020529?lang=en_us&edition=fundamental","pubTime":"2026-04-17 20:03","pubTimestamp":1776427420,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals scheduled new Phase 2b PROGRESS data on pilavapadin in diabetic peripheral neuropathic pain for presentation April 22 at American Academy of Neurology annual meeting in Chicago.Updated findings supported selection of 10 mg as dose for Phase 3 development, based on improved patient-reported pain outcomes versus placebo.Tolerability profile for 10 mg over eight weeks remained broadly comparable to placebo, with few treatment-related discontinuations.Additional preclinical results on pilavapadin in spasticity models of multiple sclerosis or spinal cord injury are set for poster presentation April 20, expanding focus on AAK1 pathway in neurologic disease.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nNDL8ssTdb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","SG9999014005.SGD","LU0314104364.USD","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","SG9999014013.SGD","IE00BKPKM429.USD","IE00BN0W2V16.EUR","BK4007","IE00BN0W2W23.USD","SG9999014039.USD","IE00B64PRP62.GBP","NDAQ","LXRX","BK4139","BK4588","LU2210150020.SGD","LU2210149790.SGD","SG9999014021.USD","BK4112","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621064606","title":"Lexicon to present Phase 3 SCORED and SOTA-P-CARDIA sotagliflozin data at ACC 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2621064606","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621064606?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:05","pubTimestamp":1774353906,"startTime":"0","endTime":"0","summary":"Lexicon announced three presentations of sotagliflozin clinical data that will be presented at the American College of Cardiology Annual Scientific Session & Expo in New Orleans, held March 28-30.One presentation will report a prespecified Phase 3 SCORED analysis stratified by baseline body mass index, showing reductions in heart failure and major adverse cardiovascular events irrespective of BMI.Two additional presentations will report analyses from the randomized, double-blind, placebo-controlled SOTA-P-CARDIA trial in symptomatic HFpEF patients without diabetes, including improved health-related quality of life and physical limitation versus placebo.Another SOTA-P-CARDIA analysis will describe findings on selective reduction of epicardial adipose tissue and hepatic fat with sotagliflozin.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL3nxbz9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","SG9999014013.SGD","LU2095319765.USD","SG9999014005.SGD","IE00BN0W2W23.USD","BK4139","BK4588","LU2210149790.SGD","BK4007","LXRX","LU2210150020.SGD","SG9999014021.USD","IE00BKPKM429.USD","SG9999014039.USD","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","BK4112","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","BK4585","NDAQ","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.lexpharma.com","stockEarnings":[{"period":"1week","weight":-0.0314},{"period":"1month","weight":0.1868},{"period":"3month","weight":0.4694},{"period":"6month","weight":0.6119},{"period":"1year","weight":2.2727},{"period":"ytd","weight":0.8783}],"compareEarnings":[{"period":"1week","weight":0.0088},{"period":"1month","weight":0.0484},{"period":"3month","weight":0.0815},{"period":"6month","weight":0.1314},{"period":"1year","weight":0.2788},{"period":"ytd","weight":0.0934}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.538462,"avgChangeRate":0.040884},{"month":2,"riseRate":0.423077,"avgChangeRate":-0.046623},{"month":3,"riseRate":0.5,"avgChangeRate":-0.016324},{"month":4,"riseRate":0.461538,"avgChangeRate":0.013505},{"month":5,"riseRate":0.518519,"avgChangeRate":0.040666},{"month":6,"riseRate":0.653846,"avgChangeRate":0.134775},{"month":7,"riseRate":0.5,"avgChangeRate":0.021487},{"month":8,"riseRate":0.269231,"avgChangeRate":-0.025279},{"month":9,"riseRate":0.346154,"avgChangeRate":0.011129},{"month":10,"riseRate":0.538462,"avgChangeRate":-0.006481},{"month":11,"riseRate":0.384615,"avgChangeRate":-0.041818},{"month":12,"riseRate":0.461538,"avgChangeRate":0.062158}],"exchange":"NASDAQ","name":"Lexicon Pharmaceuticals","nameEN":"Lexicon Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Lexicon Pharmaceuticals(LXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Lexicon Pharmaceuticals(LXRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Lexicon Pharmaceuticals,LXRX,Lexicon Pharmaceuticals股票,Lexicon Pharmaceuticals股票老虎,Lexicon Pharmaceuticals股票老虎国际,Lexicon Pharmaceuticals行情,Lexicon Pharmaceuticals股票行情,Lexicon Pharmaceuticals股价,Lexicon Pharmaceuticals股市,Lexicon Pharmaceuticals股票价格,Lexicon Pharmaceuticals股票交易,Lexicon Pharmaceuticals股票购买,Lexicon Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Lexicon Pharmaceuticals(LXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Lexicon Pharmaceuticals(LXRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}